ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Isis Pharma Inks RNA Deal With J&J

by Ann M. Thayer
January 12, 2015 | APPEARED IN VOLUME 93, ISSUE 2

Isis Pharmaceuticals will work with Janssen Biotech, part of Johnson & Johnson, to develop RNA-targeted drugs against autoimmune disorders of the gastrointestinal tract. Janssen has expertise in formulating drugs that can be delivered to targets in the gut. J&J will pay Isis $35 million up front. The agreement covers three programs for which Isis could receive another $800 million in license fees and milestone payments. If Janssen licenses promising drug candidates, it will handle the development, regulatory, and commercialization aspects.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment